Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baptist Gallwitz

Showing results (61-70 of 126) with videos related to

Pageof 13
Sort By:
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 12, 2025
Diabetes in HospitalsKarsten Müssig, Baptist Gallwitz, Thomas Haak, et al.
Regulatory Peptides|February 5, 2004
Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1Michael A Nauck, Jörg Walberg, Arndt Vethacke, et al.
European Journal of Pharmacology|May 15, 2002
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectivesJuris J Meier, Baptist Gallwitz, Wolfgang E Schmidt, et al.
Diabetes Care|August 30, 2008
Variation in the CDKAL1 gene is associated with the titer of antibodies to GADAxel Haupt, Martina Guthoff, Baptist Gallwitz, et al.
International Journal of Geriatric Psychiatry|June 12, 2009
Increased occurrence of severe episodes in elderly depressed patients with elevated anti-thyroid antibody levelsThomas Leyhe, Mirjam Hügle, Baptist Gallwitz, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weeklyJonathan E Shaw, Baptist Gallwitz, Jenny Han, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|October 29, 2021
The incretin/glucagon system as a target for pharmacotherapy of obesityStefano Del Prato, Baptist Gallwitz, Jens Juul Holst, et al.
Regulatory Peptides|July 26, 2002
Gastric inhibitory polypeptide: the neglected incretin revisitedJuris J Meier, Michael A Nauck, Wolfgang E Schmidt, et al.
Lancet (London, England)|July 23, 2002
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromesJuris J Meier, Baptist Gallwitz, Wolfgang E Schmidt, et al.
Diabetes Care|October 31, 2009
Incretin-based therapies: viewpoints on the way to consensusMichael A Nauck, Tina Vilsbøll, Baptist Gallwitz, et al.
Pageof 13

Showing results (61-70 of 126) with videos related to

Sort By:
Pageof 13
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 12, 2025
Diabetes in HospitalsKarsten Müssig, Baptist Gallwitz, Thomas Haak, et al.
Regulatory Peptides|February 5, 2004
Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1Michael A Nauck, Jörg Walberg, Arndt Vethacke, et al.
European Journal of Pharmacology|May 15, 2002
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectivesJuris J Meier, Baptist Gallwitz, Wolfgang E Schmidt, et al.
Diabetes Care|August 30, 2008
Variation in the CDKAL1 gene is associated with the titer of antibodies to GADAxel Haupt, Martina Guthoff, Baptist Gallwitz, et al.
International Journal of Geriatric Psychiatry|June 12, 2009
Increased occurrence of severe episodes in elderly depressed patients with elevated anti-thyroid antibody levelsThomas Leyhe, Mirjam Hügle, Baptist Gallwitz, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weeklyJonathan E Shaw, Baptist Gallwitz, Jenny Han, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|October 29, 2021
The incretin/glucagon system as a target for pharmacotherapy of obesityStefano Del Prato, Baptist Gallwitz, Jens Juul Holst, et al.
Regulatory Peptides|July 26, 2002
Gastric inhibitory polypeptide: the neglected incretin revisitedJuris J Meier, Michael A Nauck, Wolfgang E Schmidt, et al.
Lancet (London, England)|July 23, 2002
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromesJuris J Meier, Baptist Gallwitz, Wolfgang E Schmidt, et al.
Diabetes Care|October 31, 2009
Incretin-based therapies: viewpoints on the way to consensusMichael A Nauck, Tina Vilsbøll, Baptist Gallwitz, et al.
Pageof 13